Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6006 immunogenicity and safety in healthy adults
NCT05439824Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2022
- Primary completion
- Jan 2023
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6006 in coronavirus disease 2019 (COVID-19), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
SYS6006
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05439824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439824.